CA2396401A1 - Nouvel homologue du fgf, zfgf12 - Google Patents

Nouvel homologue du fgf, zfgf12 Download PDF

Info

Publication number
CA2396401A1
CA2396401A1 CA002396401A CA2396401A CA2396401A1 CA 2396401 A1 CA2396401 A1 CA 2396401A1 CA 002396401 A CA002396401 A CA 002396401A CA 2396401 A CA2396401 A CA 2396401A CA 2396401 A1 CA2396401 A1 CA 2396401A1
Authority
CA
Canada
Prior art keywords
residue
polypeptide
sequence
cells
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002396401A
Other languages
English (en)
Inventor
Darrell C. Conklin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2396401A1 publication Critical patent/CA2396401A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La présente invention concerne des molécules polynucléotidiques et polypeptidiques du zFGF12, un nouveau membre de la famille des FGF. La présente invention concerne également des anticorps des polypeptides du zFGF12, et des méthodes d'utilisation des polynucléotides et des polypeptides.
CA002396401A 2000-01-05 2001-01-04 Nouvel homologue du fgf, zfgf12 Abandoned CA2396401A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47806200A 2000-01-05 2000-01-05
US09/478,062 2000-01-05
PCT/US2001/000238 WO2001049740A1 (fr) 2000-01-05 2001-01-04 Nouvel homologue du fgf, zfgf12

Publications (1)

Publication Number Publication Date
CA2396401A1 true CA2396401A1 (fr) 2001-07-12

Family

ID=23898370

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002396401A Abandoned CA2396401A1 (fr) 2000-01-05 2001-01-04 Nouvel homologue du fgf, zfgf12

Country Status (5)

Country Link
EP (1) EP1246843A1 (fr)
JP (1) JP2003518944A (fr)
AU (1) AU2759201A (fr)
CA (1) CA2396401A1 (fr)
WO (1) WO2001049740A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1947182A1 (fr) * 2000-02-15 2008-07-23 Amgen Inc. Molécules 23 à facteur de croissance de fibroblaste et utilisations associées
EP1257645A2 (fr) * 2000-02-15 2002-11-20 Amgen Inc. Molecules du facteur 23 de croissance de fibroblastes et procedes d'utilisation correspondants
WO2001066596A2 (fr) * 2000-03-08 2001-09-13 Chiron Corporation Gene humain fgf-23 et produits d'expression genique
EP1261638A2 (fr) * 2000-03-08 2002-12-04 Chiron Corporation Gene humain fgf-23 et produits d'expression associes
US7223563B2 (en) 2000-07-19 2007-05-29 Advanced Research And Technology Institute Fibroblast growth factor (FGF23) nucleic acids
CN100387713C (zh) * 2000-08-11 2008-05-14 麒麟医药株式会社 调节磷酸代谢,钙代谢,钙化和维生素d代谢的多肽及其编码dna
CA2471656C (fr) * 2001-12-28 2012-07-31 Kirin Beer Kabushiki Kaisha Anticorp diriges contre le facteur de croissance 23 des fibroblastes
EP1728514A1 (fr) * 2005-06-03 2006-12-06 Immunotech S.A. Utilisations d'oligonucléotides stimulateurs de cellules souches mésenchymateuses
US7883705B2 (en) 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
WO2013006486A2 (fr) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, utilisations et procédés pour le traitement de troubles et de maladies métaboliques
WO2014085365A2 (fr) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions et méthodes de traitement de troubles et maladies métaboliques
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
IL292303A (en) 2012-12-27 2022-06-01 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostatsis and treatment of bile acid disorders and disease
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
SG11201602870YA (en) 2013-10-28 2016-05-30 Ngm Biopharmaceuticals Inc Cancer models and associated methods
PL3097122T3 (pl) 2014-01-24 2020-10-19 Ngm Biopharmaceuticals, Inc. Przeciwciała wiążące domenę 2 beta klotho oraz sposoby ich stosowania
WO2015183890A2 (fr) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Méthodes et compositions pour le traitement de maladies et de troubles métaboliques
WO2015195509A2 (fr) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Procédés et utilisations pour la modulation de l'homéostasie de l'acide biliaire et le traitement de troubles et maladies de l'acide biliaire
WO2016065106A1 (fr) 2014-10-23 2016-04-28 Ngm Biopharmaceuticals, Inc. Compositions pharmaceutiques comprenant des variants de peptide et leurs procédés d'utilisation
WO2016073855A1 (fr) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Procédés de traitement de troubles liés à l'acide biliaire et prédiction de la sensibilité clinique au traitement de troubles liés aux acides biliaires
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
AU2016353988B2 (en) 2015-11-09 2019-09-26 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
WO2018039557A1 (fr) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Méthodes de traitement de cancers et de tumeurs à médiation assurée par le facteur de croissance des fibroblastes 19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000198A1 (fr) * 1987-07-07 1989-01-12 Biotechnology Research Associates, J.V. Facteurs de croissance de fibroblastes recombinants
US5859208A (en) * 1988-07-06 1999-01-12 Fiddes; John C. Human basic fibroblast growth factor analog
AU712297B2 (en) * 1995-06-05 1999-11-04 Human Genome Sciences, Inc. Fibroblast growth factor 11
KR100506786B1 (ko) * 1997-11-25 2005-08-08 제넨테크, 인크. 섬유아세포 성장인자-19

Also Published As

Publication number Publication date
WO2001049740A1 (fr) 2001-07-12
JP2003518944A (ja) 2003-06-17
AU2759201A (en) 2001-07-16
EP1246843A1 (fr) 2002-10-09

Similar Documents

Publication Publication Date Title
US20080124759A1 (en) Novel fgf homolog zfgf12
US20020081663A1 (en) Novel FGF homolog ZFGF11
WO2001049849A1 (fr) Zfgf11 : nouvel homologue de fgf
EP1246843A1 (fr) Nouvel homologue du fgf, zfgf12
KR100611063B1 (ko) 섬유아세포 성장인자 상동체
KR100886276B1 (ko) 인산 대사, 칼슘 대사, 석회화 및 비타민 ｄ 대사를조절하는 폴리펩티드 및 그것을 코딩하는 ｄｎａ
US6518236B1 (en) FGF homologs
WO1999055869A1 (fr) Nouveaux facteurs et materiels de croissance polypeptidiques et leurs procedes de production
WO1999032515A2 (fr) Homologue de l'angiopoietine, adn le codant et procede de production dudit homologue
US6395890B1 (en) Nucleic acids encoding connective tissue growth factor homologs
US20020031805A1 (en) Novel FGF homolog zFGF10
US6531576B1 (en) Four-helical bundle protein zsig81
WO2001047957A2 (fr) NOUVEL HOMOLOGUE zFGF10 DE LA FAMILLE FGF
WO2001012665A2 (fr) Cytokine zalpha48 a enroulement en helice
EP1181369B1 (fr) Proteine en faisceau a quatre helices zsig81
EP1268804A2 (fr) Proteine helicoidale zalpha51
EP1054967A1 (fr) Homologues du facteur de croissance pour le tissu conjonctif
US20030153050A1 (en) Helical polypeptide zalpha29
WO2001018205A1 (fr) Polypeptide secrete zalpha30
US20020009775A1 (en) Helical protein zalpha51
CA2377580A1 (fr) Polypeptide spirale zalpha29
WO2001029223A2 (fr) Proteine de membrane ztsl1 de type 1
CA2374412A1 (fr) Proteine-31 a helice alpha secretee

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead